

# Anti-TNFSF5 / CD40L / CD154 Reference Antibody (ruplizumab)

Recombinant Antibody  
Catalog # APR10343

## Product Information

---

<b>Application</b>	FC, Kinetics, Animal Model
<b>Primary Accession</b>	<a href="#">P29965</a>
<b>Reactivity</b>	Human
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1
<b>Calculated MW</b>	29274

## Additional Information

---


<b>Target/Specificity</b>	TNFSF5 / CD40L / CD154
<b>Endotoxin Conjugation</b>	Unconjugated
<b>Expression system</b>	CHO Cell
<b>Format</b>	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

## Protein Information


---

<b>Name</b>	CD40LG
<b>Synonyms</b>	CD40L, TNFSF5, TRAP
<b>Function</b>	Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed: <a href="#">1280226</a> , PubMed: <a href="#">31331973</a> ). Costimulates T-cell proliferation and cytokine production (PubMed: <a href="#">8617933</a> ). Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed: <a href="#">8617933</a> ). Induces the activation of NF-kappa-B (PubMed: <a href="#">15067037</a> , PubMed: <a href="#">31331973</a> ). Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed: <a href="#">15067037</a> ). Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed: <a href="#">15067037</a> ). Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity).
<b>Cellular Location</b>	Cell membrane; Single-pass type II membrane protein. Cell surface
<b>Tissue Location</b>	Specifically expressed on activated CD4+ T- lymphocytes

# Images



Anti-TNFSF5 / CD40L / CD154 Reference Antibody (ruplizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF5 / CD40L / CD154 Reference Antibody (ruplizumab) is more than 99% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.